X4 Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell XFOR and other ETFs, options, and stocks.

About XFOR

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. 

CEO
Paula S. Ragan, PhD
CEOPaula S. Ragan, PhD
Employees
143
Employees143
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2010
Founded2010
Employees
143
Employees143

XFOR Key Statistics

Market cap
277.25M
Market cap277.25M
Price-Earnings ratio
-0.24
Price-Earnings ratio-0.24
Dividend yield
Dividend yield
Average volume
3.06M
Average volume3.06M
High today
$3.70
High today$3.70
Low today
$3.49
Low today$3.49
Open price
$3.62
Open price$3.62
Volume
355.37K
Volume355.37K
52 Week high
$26.83
52 Week high$26.83
52 Week low
$1.35
52 Week low$1.35

Stock Snapshot

With a market cap of 277.25M, X4 Pharmaceuticals(XFOR) trades at $3.50. The stock has a price-to-earnings ratio of -0.24.

During the trading session on 2025-11-06, X4 Pharmaceuticals(XFOR) shares reached a daily high of $3.70 and a low of $3.49. At a current price of $3.50, the stock is +0.3% higher than the low and still -5.4% under the high.

Trading volume for X4 Pharmaceuticals(XFOR) stock has reached 355.37K, versus its average volume of 3.06M.

The stock's 52-week range extends from a low of $1.35 to a high of $26.83.

The stock's 52-week range extends from a low of $1.35 to a high of $26.83.

XFOR News

Nasdaq 1d
X4 Pharmaceuticals Reports Q3 Loss, Misses Revenue Estimates

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $...

X4 Pharmaceuticals Reports Q3 Loss, Misses Revenue Estimates
TipRanks 1d
X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)

Reports Q3 revenue $199,000, consensus $1.9M. “The third quarter of 2025 was a time of corporate restructuring at X4 with the start of a new leadership team and...

People also own

Based on the portfolios of people who own XFOR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.